Search

everythinglearnresearchcommunity

for

Search:↓

Hirsutism is a strong sign of high male hormones and metabolic problems in women with PCOS, but acne and hair loss are not.

Low SHBG and high FAI, FT, and DHEAS levels are effective in identifying PCOS.

Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.

Neurosteroids show promise for treating epilepsy and more research is needed.

Myo-inositol helps improve skin conditions and metabolic profiles in young women with PCOS.

Metabolic syndrome and PCOS are related but separate conditions, with metabolic syndrome increasing the risk of heart disease and diabetes.

Young Czech women with PCOS have a higher risk of heart problems and should be regularly checked for cholesterol and glucose issues.

Female pattern hair loss is common, linked to polycystic ovarian syndrome, and treated with topical Minoxidil.

AMH helps estimate ovarian reserve but doesn't predict pregnancy chances; age is more important.

Women with PCOS are more likely to have sleep apnea, mainly if they are obese.

Antiandrogen treatments combined with oral contraceptives can help manage hair growth and hair loss in women with PCOS.

About 13% of women had idiopathic hirsutism and 8.5% had polycystic ovary syndrome in a group of Iranian women.

Testosterone replacement may improve sexual desire and bone health in women with low androgen levels, but more research is needed on its long-term safety.

Certain microRNAs in the fluid around eggs are linked to Polycystic Ovary Syndrome and may help diagnose it.

Spironolactone improved blood vessel function and cholesterol levels in non-obese women with PCOS.

Flutamide reduces hair growth better but has more side effects.

DHEA did not improve sexual function, well-being, or menopausal symptoms in postmenopausal women with low libido but caused side effects like acne and increased facial hair.

The skin's ability to produce hormones is linked to various skin conditions, and better understanding this process could lead to new treatments.

Hair diversity is influenced by complex genetics and environmental factors, requiring more research for practical solutions.

Plant steroid hormones show growth, health, and medicinal benefits in various organisms, including potential for treating diseases.

Obese women with PCOS are more likely to have fatty liver disease.

Gonadal dysgenesis, like Turner's and Klinefelter's syndromes, negatively affects bone health, but hormone treatments can help.

Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.

The conclusion is that hirsutism should be diagnosed and treated because it affects quality of life and may signal other health problems.

Some women with PCOS have CYP21 mutations and IRS1 variants, but these genetic factors are not major contributors to PCOS.

Hirsutism can be caused by various conditions besides PCOS, and it's important to treat the underlying issue and manage symptoms with medication and cosmetic approaches.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Finasteride and flutamide effectively reduce hirsutism in PCOS women, with flutamide also lowering hormone levels.

Natural molecules like inositols, resveratrol, vitamins, and omega-3 fatty acids may help manage Polycystic Ovary Syndrome (PCOS), but their effects vary and need more exploration.

Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.